Zinc and Upper Respiratory Tract Infections (Evidence & Dosing)
Evidence-based clinical review of zinc acetate and gluconate lozenges for the common cold: therapeutic window, dosing, and safety considerations.
The Clinical Evidence: What the Cochrane Reviews Show
Upper respiratory tract infections (URTIs / the common cold) are the most frequent viral infections encountered in primary care, predominantly caused by rhinoviruses, coronaviruses, and adenoviruses. Because antibiotics have zero efficacy against viral pathogens, identifying effective evidence-based symptomatic interventions is a clinical priority.
Rigorous systematic reviews and meta-analyses (including Cochrane systematic reviews and individual patient data meta-analyses) demonstrate that oral zinc lozenges can shorten the duration of common cold symptoms by approximately 2 to 3 days, provided specific clinical criteria are strictly met.
Mechanism of Action: Local Oropharyngeal Inhibition
Zinc does not work primarily through systemic immune absorption when treating acute colds. Rather, when an oral lozenge slowly dissolves in the mouth, free positively charged ionic zinc ($Zn^{2+}$) is released locally across the oropharyngeal mucosa:
- Inhibition of Viral Replication: High local concentrations of ionic zinc directly inhibit rhinovirus RNA polymerase and halt viral polyprotein processing.
- Receptor Binding Competition: Ionic zinc binds to viral capsid grooves and competes for intercellular adhesion molecule-1 (ICAM-1) receptor sites on mucosal epithelial cells, reducing viral docking and cellular penetration.
- Anti-inflammatory Cytokine Modulation: Blunts excessive local inflammatory mediator release in the throat and pharynx.
Critical Success Factors: Formulation, Timing & Dosing
For zinc to exert a proven therapeutic effect, three strict clinical parameters must be satisfied:
- Initiation Within 24 Hours: Treatment must commence within 24 hours of the very first cold symptom (scratchy throat, sneezing, rhinitis). Starting zinc several days into an infection yields no meaningful clinical benefit.
- Correct Chemical Formulation: Lozenges containing zinc acetate or zinc gluconate without strong chelating flavour additives (such as citric acid, tartaric acid, or sorbitol) provide the highest proportion of free, unchelated ionic zinc.
- Adequate Daily Dose: Clinical trials confirm that a total daily dose of at least 75 mg of elemental zinc (divided into lozenges dissolved every 2–3 hours while awake for 3 to 5 days) is required. Low-dose multivitamin tablets containing 5–10 mg of zinc have no detectable clinical efficacy against colds.
Side Effects & Paediatric Caution
Common short-term side effects of high-dose zinc lozenges include a metallic aftertaste and mild nausea. Taking lozenges on a full stomach mitigates nausea.
Zinc lozenges represent a potential choking hazard in young children and are not recommended for children under 5 years of age. Prolonged high-dose zinc supplementation (>2 weeks) must be avoided to prevent secondary copper deficiency and haematological cytopenias.